WO2006126675A1 - 皮膚外用剤 - Google Patents
皮膚外用剤 Download PDFInfo
- Publication number
- WO2006126675A1 WO2006126675A1 PCT/JP2006/310555 JP2006310555W WO2006126675A1 WO 2006126675 A1 WO2006126675 A1 WO 2006126675A1 JP 2006310555 W JP2006310555 W JP 2006310555W WO 2006126675 A1 WO2006126675 A1 WO 2006126675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- extract
- skin
- cyanobacteria
- derivatives
- Prior art date
Links
- 239000000284 extract Substances 0.000 claims abstract description 212
- 230000000694 effects Effects 0.000 claims abstract description 92
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 22
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims description 70
- 230000002087 whitening effect Effects 0.000 claims description 59
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 48
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 40
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 40
- 229940097275 indigo Drugs 0.000 claims description 40
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 27
- 230000008099 melanin synthesis Effects 0.000 claims description 26
- 230000002401 inhibitory effect Effects 0.000 claims description 25
- 229960005070 ascorbic acid Drugs 0.000 claims description 23
- 239000002211 L-ascorbic acid Substances 0.000 claims description 20
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 20
- 244000025254 Cannabis sativa Species 0.000 claims description 19
- 229960004705 kojic acid Drugs 0.000 claims description 19
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 19
- 208000028169 periodontal disease Diseases 0.000 claims description 18
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 16
- 229930182470 glycoside Natural products 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000003205 fragrance Substances 0.000 claims description 12
- 210000002374 sebum Anatomy 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims description 12
- 235000019626 lipase activity Nutrition 0.000 claims description 11
- 210000001732 sebaceous gland Anatomy 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 229960000401 tranexamic acid Drugs 0.000 claims description 9
- 150000002338 glycosides Chemical class 0.000 claims description 7
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 claims description 5
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 5
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 5
- 229920002079 Ellagic acid Polymers 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 229960002852 ellagic acid Drugs 0.000 claims description 5
- 235000004132 ellagic acid Nutrition 0.000 claims description 5
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 5
- KTRRXJQAOOYSDA-UHFFFAOYSA-N 1,7-bis(4-hydroxyphenyl)heptane-3,5-dione Chemical compound C1=CC(O)=CC=C1CCC(=O)CC(=O)CCC1=CC=C(O)C=C1 KTRRXJQAOOYSDA-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical class OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 4
- 230000002000 scavenging effect Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 229930188104 Alkylresorcinol Natural products 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 208000003265 stomatitis Diseases 0.000 claims description 3
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 claims description 3
- 201000004647 tinea pedis Diseases 0.000 claims description 3
- 229920003169 water-soluble polymer Polymers 0.000 claims description 3
- CGFPNELNAZZYQL-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CGFPNELNAZZYQL-RXSVEWSESA-N 0.000 claims description 2
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000010201 Exanthema Diseases 0.000 claims description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 claims description 2
- 241000382362 Persicaria tinctoria Species 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000005884 exanthem Diseases 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- HJFYFYWETUVIHT-UHFFFAOYSA-N tetrahydrodemethoxycurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=CC(O)=CC=2)=C1 HJFYFYWETUVIHT-UHFFFAOYSA-N 0.000 claims description 2
- 241001062009 Indigofera Species 0.000 abstract description 40
- 239000000419 plant extract Substances 0.000 abstract description 13
- 239000003112 inhibitor Substances 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011440 grout Substances 0.000 abstract 1
- 241000192700 Cyanobacteria Species 0.000 description 128
- 210000003491 skin Anatomy 0.000 description 101
- -1 pH adjusters Substances 0.000 description 82
- 238000012360 testing method Methods 0.000 description 52
- 239000000047 product Substances 0.000 description 45
- 235000002639 sodium chloride Nutrition 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 35
- 241000894006 Bacteria Species 0.000 description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 27
- 239000010437 gem Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 25
- 230000003712 anti-aging effect Effects 0.000 description 24
- 230000000844 anti-bacterial effect Effects 0.000 description 24
- 210000000214 mouth Anatomy 0.000 description 21
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 20
- 229910001751 gemstone Inorganic materials 0.000 description 19
- 230000009471 action Effects 0.000 description 18
- 238000007796 conventional method Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 17
- 239000008213 purified water Substances 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 235000011187 glycerol Nutrition 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 14
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 14
- 206010042496 Sunburn Diseases 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000006210 lotion Substances 0.000 description 13
- 230000001629 suppression Effects 0.000 description 13
- 206010015150 Erythema Diseases 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 12
- 231100000321 erythema Toxicity 0.000 description 12
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 12
- 230000001766 physiological effect Effects 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 230000002265 prevention Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 229940058015 1,3-butylene glycol Drugs 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 235000019437 butane-1,3-diol Nutrition 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 239000000606 toothpaste Substances 0.000 description 10
- 229940034610 toothpaste Drugs 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 210000004761 scalp Anatomy 0.000 description 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 239000004367 Lipase Substances 0.000 description 8
- 102000004882 Lipase Human genes 0.000 description 8
- 108090001060 Lipase Proteins 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 235000019421 lipase Nutrition 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 7
- 229930003270 Vitamin B Natural products 0.000 description 7
- 239000006096 absorbing agent Substances 0.000 description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 7
- 229940074360 caffeic acid Drugs 0.000 description 7
- 235000004883 caffeic acid Nutrition 0.000 description 7
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 235000019156 vitamin B Nutrition 0.000 description 7
- 239000011720 vitamin B Substances 0.000 description 7
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 6
- 240000008620 Fagopyrum esculentum Species 0.000 description 6
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002849 elastaseinhibitory effect Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 229960003720 enoxolone Drugs 0.000 description 6
- 150000002148 esters Chemical group 0.000 description 6
- 229940074391 gallic acid Drugs 0.000 description 6
- 235000004515 gallic acid Nutrition 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229940025878 hesperidin Drugs 0.000 description 6
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 6
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000001382 Experimental Melanoma Diseases 0.000 description 5
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000004166 Lanolin Substances 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 5
- 229960000271 arbutin Drugs 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 230000003779 hair growth Effects 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 229940039717 lanolin Drugs 0.000 description 5
- 235000019388 lanolin Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 5
- 230000003239 periodontal effect Effects 0.000 description 5
- 230000019612 pigmentation Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 231100000245 skin permeability Toxicity 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 4
- AUZQQIPZESHNMG-UHFFFAOYSA-N 3-methoxysalicylic acid Chemical compound COC1=CC=CC(C(O)=O)=C1O AUZQQIPZESHNMG-UHFFFAOYSA-N 0.000 description 4
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 240000004343 Indigofera suffruticosa Species 0.000 description 4
- 241000241413 Propolis Species 0.000 description 4
- 239000004373 Pullulan Substances 0.000 description 4
- 229920001218 Pullulan Polymers 0.000 description 4
- 206010040954 Skin wrinkling Diseases 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 239000000551 dentifrice Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 4
- 235000010449 maltitol Nutrition 0.000 description 4
- 239000000845 maltitol Substances 0.000 description 4
- 229940035436 maltitol Drugs 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 229940051866 mouthwash Drugs 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 4
- 229940069949 propolis Drugs 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000019423 pullulan Nutrition 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- 229940043375 1,5-pentanediol Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 3
- 240000001341 Reynoutria japonica Species 0.000 description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 241001122767 Theaceae Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000003788 bath preparation Substances 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- 235000014692 zinc oxide Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- PLISWQKGWPUZID-UHFFFAOYSA-N 2-hydroxy-4-methoxybenzoic acid;potassium Chemical compound [K].COC1=CC=C(C(O)=O)C(O)=C1 PLISWQKGWPUZID-UHFFFAOYSA-N 0.000 description 2
- AAUQLHHARJUJEH-UHFFFAOYSA-N 2-hydroxy-5-methoxybenzoic acid Natural products COC1=CC=CC(O)=C1C(O)=O AAUQLHHARJUJEH-UHFFFAOYSA-N 0.000 description 2
- FERWBXLFSBWTDE-UHFFFAOYSA-N 3-aminobutan-2-ol Chemical compound CC(N)C(C)O FERWBXLFSBWTDE-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- 241001464430 Cyanobacterium Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 244000111489 Gardenia augusta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940124274 edetate disodium Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012860 organic pigment Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 229940082004 sodium laurate Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- AFQOCSDOKGNDNA-OBEHBXMUSA-N (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one (Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCC\C=C/CCCCCCCC(O)=O AFQOCSDOKGNDNA-OBEHBXMUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IRVNEGRHQKGRGD-WPXUHFOISA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O IRVNEGRHQKGRGD-WPXUHFOISA-N 0.000 description 1
- PBTPTBMYJPCXRQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O PBTPTBMYJPCXRQ-MGMRMFRLSA-N 0.000 description 1
- MHUOEHQATDLJFZ-WPXUHFOISA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O MHUOEHQATDLJFZ-WPXUHFOISA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- NKQFKJYKCVDLPT-KHPPLWFESA-N (4-methyl-2-oxochromen-7-yl) (z)-octadec-9-enoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C21 NKQFKJYKCVDLPT-KHPPLWFESA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- NMUWSGQKPAEPBA-UHFFFAOYSA-N 1,2-dibutylbenzene Chemical compound CCCCC1=CC=CC=C1CCCC NMUWSGQKPAEPBA-UHFFFAOYSA-N 0.000 description 1
- FVUGZKDGWGKCFE-UHFFFAOYSA-N 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCCC2=C1CC(C(C)=O)(C)C(C)C2 FVUGZKDGWGKCFE-UHFFFAOYSA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BVYZDBLMCKSKAT-UHFFFAOYSA-N 2,2,3,3-tetrahexyldecanoic acid Chemical compound CCCCCCCC(CCCCCC)(CCCCCC)C(CCCCCC)(CCCCCC)C(O)=O BVYZDBLMCKSKAT-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- GOHZKUSWWGUUNR-UHFFFAOYSA-N 2-(4,5-dihydroimidazol-1-yl)ethanol Chemical compound OCCN1CCN=C1 GOHZKUSWWGUUNR-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- JUIYTAQAHOONSH-UHFFFAOYSA-N 2-hydroxy-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C(O)=C1 JUIYTAQAHOONSH-UHFFFAOYSA-N 0.000 description 1
- IXKMJGZLCSWMTD-UHFFFAOYSA-N 2-hydroxy-4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C(O)=C1 IXKMJGZLCSWMTD-UHFFFAOYSA-N 0.000 description 1
- VHCJSVNQEBEVMO-UHFFFAOYSA-N 2-hydroxy-5-propoxybenzoic acid Chemical compound CCCOC1=CC=C(O)C(C(O)=O)=C1 VHCJSVNQEBEVMO-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ABGZWIFTZXUDGF-UHFFFAOYSA-N 3-(4-methylphenyl)propanal Chemical compound CC1=CC=C(CCC=O)C=C1 ABGZWIFTZXUDGF-UHFFFAOYSA-N 0.000 description 1
- DTFQMPQJMDEWKJ-UHFFFAOYSA-N 3-ethoxybenzoic acid Chemical compound CCOC1=CC=CC(C(O)=O)=C1 DTFQMPQJMDEWKJ-UHFFFAOYSA-N 0.000 description 1
- SOFRHZUTPGJWAM-UHFFFAOYSA-N 3-hydroxy-4-[(2-methoxy-5-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound COc1ccc(cc1N=Nc1c(O)c(cc2ccccc12)C(=O)Nc1cccc(c1)[N+]([O-])=O)[N+]([O-])=O SOFRHZUTPGJWAM-UHFFFAOYSA-N 0.000 description 1
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- LRHMNPYUPIGMND-UHFFFAOYSA-N 4-(3-methylphenyl)-2h-benzotriazole Chemical compound CC1=CC=CC(C=2C=3N=NNC=3C=CC=2)=C1 LRHMNPYUPIGMND-UHFFFAOYSA-N 0.000 description 1
- JBRMEFWJFBHUKG-UHFFFAOYSA-N 4-[(diaminomethylideneamino)methyl]cyclohexane-1-carboxylic acid Chemical compound NC(N)=NCC1CCC(C(O)=O)CC1 JBRMEFWJFBHUKG-UHFFFAOYSA-N 0.000 description 1
- XHPXSMWMAJGYBS-UHFFFAOYSA-N 4-[[(4-carboxycyclohexyl)methylamino]methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CNCC1CCC(C(O)=O)CC1 XHPXSMWMAJGYBS-UHFFFAOYSA-N 0.000 description 1
- DVZPQHRWOUXUPU-UHFFFAOYSA-N 4-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C(O)=C1 DVZPQHRWOUXUPU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 244000005894 Albizia lebbeck Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000663915 Anasa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 244000294263 Arctium minus Species 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000269837 Artemisia dubia Species 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 241000512260 Ascophyllum Species 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000589996 Campylobacter rectus Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 244000251786 Cymbopogon rectus Species 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000007829 Haematoxylum campechianum Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 244000162475 Juniperus rigida Species 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-ZZWDRFIYSA-N L-galactosamine Chemical compound N[C@@H]1C(O)O[C@@H](CO)[C@@H](O)[C@H]1O MSWZFWKMSRAUBD-ZZWDRFIYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 241000183666 Nepsera aquatica Species 0.000 description 1
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 1
- MQGCKGJYRSBWCN-UHFFFAOYSA-N OC1=C(C(=O)O)C=CC(=C1)OCCCC.C(CCC)OC=1C=C(C(C(=O)O)=CC1)O Chemical compound OC1=C(C(=O)O)C=CC(=C1)OCCCC.C(CCC)OC=1C=C(C(C(=O)O)=CC1)O MQGCKGJYRSBWCN-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000427382 Osyris quadripartita Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000206755 Palmaria Species 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241001474791 Proboscis Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 241000543810 Sasa veitchii Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 241001123263 Zostera Species 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-MROZADKFSA-N aldehydo-L-ribose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-MROZADKFSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-KGJVWPDLSA-N beta-L-galactose Chemical compound OC[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-KGJVWPDLSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940017687 beta-d-ribose Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- ZCLVNIZJEKLGFA-UHFFFAOYSA-H bis(4,5-dioxo-1,3,2-dioxalumolan-2-yl) oxalate Chemical compound [Al+3].[Al+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O ZCLVNIZJEKLGFA-UHFFFAOYSA-H 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- AVKNGPAMCBSNSO-UHFFFAOYSA-N cyclohexylmethanamine Chemical compound NCC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- JZKFHQMONDVVNF-UHFFFAOYSA-N dodecyl sulfate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(O)(=O)=O JZKFHQMONDVVNF-UHFFFAOYSA-N 0.000 description 1
- CXPOFJRHCFPDRI-UHFFFAOYSA-N dodecylbenzene;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCC1=CC=CC=C1 CXPOFJRHCFPDRI-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- XXWFDPVOXNJASB-UHFFFAOYSA-N ethanol;phenol Chemical compound CCO.OC1=CC=CC=C1 XXWFDPVOXNJASB-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- WYVGZXIHGGQSQN-UHFFFAOYSA-N hexadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCCCCC(O)=O WYVGZXIHGGQSQN-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960000990 monobenzone Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- YRJKYHIIYRGTCC-UHFFFAOYSA-M potassium;2-hydroxy-4-methoxybenzoate Chemical compound [K+].COC1=CC=C(C([O-])=O)C(O)=C1 YRJKYHIIYRGTCC-UHFFFAOYSA-M 0.000 description 1
- MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- MSXHSNHNTORCAW-MPGIDXPLSA-M sodium;(3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@@H]1OC(C([O-])=O)[C@@H](O)[C@H](O)[C@@H]1O MSXHSNHNTORCAW-MPGIDXPLSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000001040 synthetic pigment Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000019669 taste disorders Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- IRJHMGSFUSXXQJ-JBEKKHDOSA-K trisodium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O IRJHMGSFUSXXQJ-JBEKKHDOSA-K 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 229940105296 zinc peroxide Drugs 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention relates to an extract of cyanobacteria and an external preparation for skin containing the same as an active ingredient, in particular, a melanin production inhibitor and an inhibitor of Z or elastase activity containing an extract by a solvent containing water from cyanobacteria.
- the present invention relates to an agent, and a skin external preparation for whitening and / or skin containing the same as an active ingredient.
- Pigmentation of skin after tanning, koi mochi, blemishes, buckwheat, and sunburn is one of the major skin problems for middle-aged and older people and women. Therefore, various skin beautifying and whitening ingredients have been proposed. Ingredients effective for such beautiful skin and whitening include, for example, kojic acid or derivatives thereof, L-ascorbic acid, tocolol roll or derivatives thereof, gnorethione, hydrogen peroxide, zinc peroxide, hydroquinone monobenzyl ether, etc.
- Animal extracts such as chemicals, placenta extract, synolec extract, Anoleni power, Anolethea, Aloe, Ogon, Enmeiso, force mitsule, Licorice, Gardenia, Sicon, Shouma, Birch, Senkiyu, Gennosho, Psycho, Wild tea Plant extracts such as eucalyptus sensu, power, nikko, safflower, garlic, roe, barley, litchi and logwood are known.
- Indigo grass is an annual herbaceous plant belonging to the family Tadeidae, which originates in southern Vietnam and is classified as a dicotyledonous flower.
- indigo leaves and fruits are said to contain useful physiologically active ingredients, and indigo leaves and indigo fruits obtained by drying the leaves and fruits are traditionally used as herbal medicines.
- foods and drinks and cosmetics which have antitumor activity, antiviral activity, antibacterial activity and the like, containing an extract of cyanobacteria have been proposed (for example, JP-A-2001-31581). Publication and JP 2004-189732 A). Disclosure of the invention
- the present invention relates to a melanin production inhibitor and / or an elastase activity inhibitor comprising as an active ingredient a plant-derived extract that has no problem in terms of stability with high safety and generation of odor and starch. It is an object of the present invention to provide a skin external preparation excellent in whitening action, skin beautifying action, and anti-aging action.
- cyanobacteria extract is It has been found to have particularly excellent melanin production inhibitory activity and elastase activity inhibitory activity, as well as various physiological activities such as lipase activity inhibitory activity and sebum secretion regulating effect from sebaceous glands. It was found that the formulated external preparation for skin exhibits excellent whitening effect, skin beautifying effect and anti-aging effect. In addition, this indigo extract can be used in combination with other skin-whitening ingredients to improve not only its whitening effect but also its anti-oxidation, anti-inflammatory, antibacterial, anti-bacterial effects. The present inventors have completed the present invention by finding an unexpected finding that physiological activities including aging are also enhanced.
- the present invention provides a melanin production inhibitor, an elastase activity inhibitor and Z or an anti-aging agent, which are blended with a cyanobacteria extract, and a skin external preparation comprising these.
- the present invention solves the above problems.
- Fig. 1 is a graph showing the relationship between the concentration of a cyanobacteria extract of the present invention and the elastase activity inhibition rate.
- FIG. 2 A graph showing the relationship between the concentration of the Cyanobacteria extract of the present invention and the lipase activity inhibition rate.
- FIG. 3 is a graph showing the relationship between the concentration of the extract of cyanobacteria according to the present invention and the rate of o 2 1 removal.
- FIG. 4 is a graph showing the relationship between the concentration of the extract of green grass of the present invention and the DPPH radical removal rate.
- "Indigo grass” used in the present invention is an annual plant (Polygonum tinctorium Lour) belonging to the family Tadeidae and is also called “Kai-in”.
- the origin and cultivation method of the cyanobacteria used in the present invention are not particularly limited. Naturally grown indigenous or cultivated mutant strains obtained by breeding these by conventional methods. Alternatively, it may be a cultured product obtained by indigo plant culture, tissue culture, callus culture, cell culture, or the like. When a plant body is used as a raw material for extraction, a part or all of the plant body can be used. In addition, these raw materials may be fresh, that is, in a state containing water, in a frozen state, in a dried state, or in a mixture thereof.
- a method for producing a Cyanobacteria extract used in the present invention the whole plant of Cyanobacteria as described above and / or a part thereof is used as a raw material, and water or a solvent containing water is added thereto.
- it can be prepared by an extraction method that is generally performed in the cosmetics industry, the pharmaceutical industry, etc., and a squeezed product of indigo grass can be used or a mixture thereof can be used.
- the above raw materials are usually used in the cosmetic industry, pharmaceutical industry, etc., in one or more types such as shredded, crushed, ground, crushed, pressed, fermented, dried and frozen.
- Solvents for preparing the extract of cyanobacteria used in the present invention include aqueous solvents (for example, water, acidic or basic aqueous solvents), alcohols (for example, methanol, anhydrous ethanol, ethanol, etc.) Or lower alcohols such as propylene glycol, 1,3-butylene glycol, etc.) and ketones such as acetone can be used in appropriate mixture.
- aqueous solvents for example, water, acidic or basic aqueous solvents
- alcohols for example, methanol, anhydrous ethanol, ethanol, etc.
- lower alcohols such as propylene glycol, 1,3-butylene glycol, etc.
- ketones such as acetone
- the mixed solvent a combination of water and ethanol is particularly desirable.
- the ethanol concentration is preferably 0% by mass to 70% by mass. 0% by mass to 60% by mass (hereinafter, referred to in this specification) Unless otherwise specified, “% by mass” is expressed as “%”.
- the extraction solvent is appropriately added with an acid, an alkali, or a buffer. It is also optional to adjust to the desired pH. The extraction is usually carried out in the range of pH 2 to pH 13, and the range of pH 4 to pH 7.5 is particularly desirable, with the range of pH 4 to pHIO being preferred.
- an appropriate amount of the above-described extraction solvent may be used with respect to the above-mentioned raw materials.
- the amount is 0.1 to 30 times, preferably 0.
- this extraction step with a solvent is usually carried out for about 0.5 to 100 hours, preferably 5 to 48 hours.
- surfactants and preservatives are used for the purpose of suppressing the generation of starch and browning, the generation of off-flavors, and the suppression of the growth of microorganisms.
- Agents moisturizers, thickeners, water-soluble polymers, antioxidants, chelating agents, dyes, fragrances, pH adjusters, vitamins including L-ascorbic acid and its derivatives, or one or two additives More than seeds can be added.
- the addition timing and addition amount of these components may be added at any time in the extraction step, as long as the effects of the present invention are not hindered.
- the extract of cyanobacteria thus extracted can be used as it is as a raw material for an external preparation for skin.
- the extract may optionally be used as a cyanobacteria extract that has been subjected to appropriate purification treatment to increase the active ingredient content in order to improve the effects of the present invention.
- the extract is purified according to the purpose of use, and its components, such as polyphenols, ananolecoids, terpenoids, steroids, phenols, pigments, saccharides, proteins, amino acids, nucleic acids, peptides It is also optional to increase or decrease the content ratio of one or more lipids.
- purification means include, for example, filtration, Concentration, centrifugation, crystallization, solvent fractionation, fractional precipitation, dialysis, hydrophobic chromatography, reverse phase chromatography, adsorption chromatography, affinity chromatography, gel filtration chromatography and / or ion exchange chromatography as appropriate
- the method is selected.
- the indigo grass extract of the present invention preferably contains 400 ⁇ g Zml or more of polyphenol, which is preferably 200 ⁇ g Zml or more, from the viewpoint of whitening action, skin beautifying action, and anti-aging strength.
- it is one of the ingredients that play an important role in the whitening, anti-aging, antibacterial, and anti-inflammatory effects of indigo extract, and it has a high content of active ingredients such as Things are desirable.
- these cyanobacteria extracts may be further subjected to treatments such as centrifugation, ultrafiltration and ultrafiltration, concentration, and drying, as necessary, physiologically or pharmacologically.
- Appropriate components may be used in appropriate forms such as liquid, solid, powder, paste, gel, semi-solid, emulsion, suspension, etc. .
- Concentration and drying methods commonly used in the normal food industry, cosmetic industry, pharmaceutical industry, etc., for example, vacuum concentration, precision membrane concentration, reverse osmosis membrane concentration, ultrafiltration concentration, vacuum drying, freeze drying, spray drying Etc. can be used in appropriate combinations.
- the extract of cyanobacteria can be dried as it is, but cyclic carbohydrates such as cyclodextrin, cyclic tetrasaccharide, cyclic pentasaccharide, ⁇ , ⁇ -trehalose, ⁇ , ⁇ -It is preferable to use carbohydrate derivatives of trehalose or carbohydrates containing these as excipients and stabilizers, and it is preferable because a homogeneous powder can be prepared with a relatively small amount of cyclodextrin. .
- cyclic carbohydrates such as cyclodextrin, cyclic tetrasaccharide, cyclic pentasaccharide, ⁇ , ⁇ -trehalose, ⁇ , ⁇ -It is preferable to use carbohydrate derivatives of trehalose or carbohydrates containing these as excipients and stabilizers, and it is preferable because a homogeneous powder can be prepared with a relatively small amount of cyclodextrin
- the cyanobacteria extract thus obtained has at least a melanin production inhibitory action, an elastase activity inhibitory action, an anti-aging action, a lipase activity inhibitory action, and a sebum secretion regulating action from the sebaceous glands.
- melanin synthesis in melanocytes caused by quality stimuli be suppressed and exerts a whitening effect, but it involves excessive nitric oxide and plastaglandin E in the body, self
- the extract of cyanobacteria can be used for infection by microorganisms such as Gram-positive bacteria, Gram-negative bacteria, fungi, and viruses, invasion or contact of foreign substances such as proteins, organic compounds, and metals, and tumors. Inflammation is caused by the suppression of production of inflammatory site force-in including tumor necrosis factor (TNF), interferon ⁇ and interleukin 1 It is possible to exert the property of adjusting the biological function so as to suppress the above.
- the indigo plant extract contains useful ingredients such as tributansrin.
- ⁇ gingivalis Prophyromonas gingivalis (abbreviated as “ ⁇ gingivalis” hereinafter) present on the tooth surface and periodontal disease pockets.
- a strong bacteriostatic action against caries such as Streptococcus mutans (hereinafter sometimes abbreviated as “S. mutans”) and Z.
- the cyanobacteria extract of the present invention is not only used as a melanin production inhibitor, an elastase activity inhibitor, an anti-aging agent, a lipase activity inhibitor, and a sebum secretion regulator of Z or sebaceous gland force.
- Antibacterial action against microorganisms such as athlete's foot, narcissus fungus, anti-inflammatory action against skin diseases such as stomatitis, dermatitis, eczema and rash, anti-aging Action, anti-periodontal disease action, pile contact action, active oxygen removal action, radical scavenging action, site force-in production regulating action or production inhibiting action, nitric oxide synthase expression suppressing action, plastaglandin synthesis
- preparations for mildly exerting enzyme activity inhibitory action and Z or biological function adjustment action it is not only external preparations for skin, such as cosmetics, pharmaceuticals, quasi drugs, but also food, drink, feed, feed, pet food, miscellaneous goods It can also be used advantageously as a manufacturing raw material.
- the cyanobacteria extract of the present invention is excellent in the effect of promoting the growth of hair papilla cells, it can only be used as an active ingredient of a hair-restoring agent. After the immersion treatment with the solution containing the grass extract, transplantation to the scalp can improve the growth rate of the transplanted hair root on the scalp.
- the amount of the indigo plant extract of the present invention added to the external preparation for skin is not particularly limited as long as the desired effect of the indigo plant extract is exhibited. It may be set as appropriate according to the strength of the action and the dosage form, but is usually 0.005% to 30% in terms of extract solids, based on the total mass of the external preparation for skin. % To 10% is desirable 0.05% to 10% is particularly desirable. The desired effect cannot be obtained at a concentration lower than 0005%, and even if it is added at 30% or more, the effect does not increase. Depending on the form of the composition, the physical properties may be affected. .
- the extract of cyanobacteria of the present invention can be used as an external preparation for skin in combination with one or more of other components having a whitening effect, thereby suppressing its melanin production and elastase activity.
- it should also enhance the known physiological activities of cyanobacteria extract such as antioxidant, anti-inflammatory and antibacterial actions Can do.
- the origin and production method of the other ingredients having a whitening effect other than this extract as long as they have a whitening action and can enhance the physiological activity of the extract.
- L-ascorbic acid and derivatives thereof and salts thereof alkoxysalicylic acids and salts thereof, glycosides of hydroquinone and derivatives thereof, tranexamic acid and derivatives thereof and salts thereof, derivatives of resorcin
- examples include kojic acid and its derivatives and their salts, ellagic acid and linoleic acid and their salts, citrus extract, and tetrahydrotalcuminoid.
- the effect of enhancing the physiological activity of the extract of cyanobacteria In terms of strength, ascorbic acid and its derivatives, and salts thereof, L-ascorbic acid 2-darcoside is particularly desirable.
- the amount to be added to the external preparation for skin is as long as there is no pharmaceutical problem.
- the total amount is 0.001% to 20% of the total mass of the topical skin preparation. If the blending amount is less than 0.001%, the enhancement effect of the whitening effect of the external preparation for skin tends to be poor, and conversely, even if it exceeds 20%, an increase in the effect is practically not expected. It tends to be difficult to add to the composition.
- a more preferable blending amount is 0.01% to 10%, particularly preferably 0.1% to 10%.
- force mitsule extract it is the amount converted to that solid.
- L-scorbic acid and its derivatives used in the present invention are not particularly limited. Specifically, for example, L-ascorbic acid and its derivatives L-ascorbic acid monostearate, L-ascorbic acid monopalmitate, L-ascorbic acid monooleate, L-ascorbic acid distearate, L-ascorbic acid dipalmitate, L- L-ascorbic acid alkyl esters such as ascorbic acid dilate; L-ascorbic acid phosphates such as L-ascorbic acid phosphates, L-ascorbic acid phosphates magnesium salts, L-ascorbic acid phosphate sodium salts and the like; L -Scorbic acid sulfate and its salts; L-ascorbic acid-2-dalcoside, which is a preferred example of L-ascorbic acid-2-darcoside, and their acylated derivatives.
- L-ascorbic acid and its derivatives L-as
- alkali metal salts or alkaline earth metal salts such as sodium salts, potassium salts, magnesium salts, and calcium salts
- salts such as ammonium salts and amino acid salts can be used in the same manner.
- an alkaline earth metal salt is preferred, and a magnesium salt is particularly preferred.
- the derivatives of L-ascorbic acid used in the present invention are L-ascorbic acid alkyl esters, L-ascorbic acid phosphates and their salts, and L-ascorbic acid from the viewpoint of stability when formulated in a skin external preparation.
- alkoxysalicylic acids used in the present invention are those in which any hydrogen atom at the 3-position, 4-position or 5-position of salicylic acid is substituted with an alkoxy group.
- Preferred examples of the alkoxy group as the substituent include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, and an isobutoxy group. A methoxy group or an ethoxy group is particularly preferable.
- alkoxysalicylic acids include 3-methoxysalicylic acid (2_hydroxy—3-methoxybenzoic acid), 3_ethoxysalitinoleic acid (2_hydroxy_3_ethoxybenzoic acid), 4-methoxysalitinino Re-acid (2-hydroxy- 4--methoxybenz oic acid), 4--ethoxy-salitinoleic acid (2--hydroxy- 4--ethoxybenzoic acid), 4--propoxy-salitinoleic acid (2--hydroxy- 4--propoxybenzoic acid) , 4 Isopropoxysalitinoleic acid (2-hydroxy- 4 isopropoxybenzoic acid), 4-Butoxysalicylic acid (2-hydroxy- 4-butoxybenzoic acid), 5 Methoxysalicylic acid (2-hydroxy-5-methoxybenzoic acid), 5 Examples thereof include acid (2-nydroxy-5-ethoxybenzoic acid) and propoxysalitinoleic acid
- alkoxysalicylic acid may be blended in the form of a salt.
- a preferred salt is 4-methoxysalicylate.
- the salt include, but are not limited to, salts such as ammonium salts and amino acid salts in addition to alkali metal salts or alkaline earth metal salts such as sodium salts, potassium salts, and calcium salts.
- potassium salt is preferred, and potassium 4-methoxysalicylate is particularly preferred.
- Hydroquinone glycosides used in the present invention include, for example, hydroquinone a_D-gnolecose, hydroquinone j3_D-gnolecose, hydrone quinone, L-gnolecose, hydroquinone / 3-L-gnolecose, and hydose Quinone HI D-galactose, hydroquinone ⁇ _D_ galactose, hydroquinone HI _L_ galactose, hydroquinone ⁇ _L_ galactose, etc., hexone sugar glycosides, hydroquinone HI D-ribose, hydroquinone ⁇ _D-ribose, hydride mouth Quinone H1 L-ribose, hydroquinone j3 _L_ ribose, Hyde mouth quinone H D arabinose, Hyde mouth quinone D arabinose, Hyde Mouth quinone one L_arabinose
- hydroquinone D-glucose and / or hydride quinone-glucose are preferred from the standpoints of whitening effect, ease of access, and stability.
- Particularly preferred is hydride quinone D glucose (generic name: arbutin, hereinafter referred to as “arbutin”).
- examples of the derivative of a hydrated quinone glycoside include an ester form such as an acetylated product and an ether form such as a methylated product.
- tranexamic acid derivative used in the present invention examples include tranexamic acid dimer (trans-4- (trans-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid and the like), tranexamic acid, and the like.
- Hydroquinone esters (trans_4_aminomethylcyclohexanecarboxylic acid 4'-hydroxyphenyl ester, etc.), tranexamic acid and gentisic acid esters (2- (trans_4_aminomethylcyclohexylcarbonyloxy)) _ 5-hydroxybenzoic acid and its salts), amide of tranexamic acid (trans _4_ methyl methyl amide and its salt, trans _4_ ( ⁇ -methoxybenzoyl) aminomethyl cyclohexane car Bonic acid and its salts, trans _4_ guanidinomethylcyclohexane carboxylic acid and its salts).
- alkylresorcinol is a typical example. Specifically, 4 ⁇ -butylresorcinol is particularly preferred, with 4_alkylresorcinol being preferred.
- examples of kojic acid derivatives include kojic acid esters such as kojic acid alkyl esters and kojic acid ethers such as kojic acid alkyl ethers. And kojic acid glycosides.
- kojic acid ethers include 2-methoxymethyl _5-hydroxyl-4H-pyran_4_one, 2_ethoxymethyl_5-hydroxy-_4H_pyran-4-one, 2_benzoluluo Ximethyl _ 5—Hydroxy mono 4H—pyran _4_one, 2-cinnamoyloxymethyl mono 5-hydroxy_ 4H—pyran _ 4 _one, 2—Phenoxymethyl mono 5—hydroxy mono 4H—pyran mono 4—one Etc.
- kojic acid esters include kojic acid palmitate and kojic acid stearate.
- kojic acid glycosides include sugars in the CH OH group at position 2 of kojic acid.
- saccharide examples include 6 carbon sugars such as glucose, galactose, mannose, fructose, and sorbose, 5 carbon sugars such as ribose, arabinose, xylose, lyxose, and xylulose, such as amino sugars such as dalcosamine, mannosamine, and galactosamine.
- examples include disaccharides such as maltose, ratatoose, cellobiose and sucrose, for example, trisaccharides such as maltotriose and cellotriose. Of these, kojic acid having a strong enhancement effect such as a whitening effect is preferred.
- the force mitsu extract used in the present invention an extract extracted from the force mitsu with an appropriate solvent can be used. Further, it can be used after adjusting operations such as concentration, deodorization, purification, and drying within the range not impairing the effects of the present invention.
- the force mitsure extract it is also possible to use a commercially available product. As an example of a commercially available product, for example, “force mitsu liquid” (manufactured by Ichimaru Falcos Co., Ltd., solid content 0.6% to 1.2%) Is mentioned.
- Examples of the tetrahydrotalcuminoids used in the present invention include those described in JP-A-6-128133, European Patent Publication No. 1108419, and the like. Specifically, for example, tetrahydrocurcumin, tetrahydrotanorecmine, tetrahydrodemethoxycurcumin, tetrahydrotanorecmine, tetrahydrobisdemethoxycurcumin and the like can be mentioned.
- tetrahydrotalcuminoids used in the present invention
- tetrahydrocurcumin can be obtained from commercially available products.
- SABI NSA tetrahydrotalcuminoid
- Cyanobacteria extract or a mixture of Cyanobacteria extract obtained by the present invention and the above-mentioned other components having a whitening effect may be used as a skin external preparation as it is.
- One or more of the pharmaceutically or physiologically acceptable ingredients other than those mentioned above can be added as long as they do not interfere. Examples of these components include water, alcohols, oil components, surfactants, preservatives (antibacterial agents), fragrances, moisturizers, thickeners, water-soluble polymers, antioxidants, chelating agents, and pH adjustments.
- the oil component includes macadamia nut oil, castor oil, olive oil, cacao oil, cocoa oil, coconut oil, tree wax, jojoba oil, grape seed oil, apogado oil, mink oil, Animal fats and oils such as egg yolk oil, waxes such as beeswax, whale wax, lanolin, carnauba wax, candelilla wax, liquid paraffin, squalane, microcrystalline wax, ceresin wax, paraffin wax, petrolatum and other hydrocarbons, power pudding Natural and synthetic fatty acids such as acid, myristic acid, palmitic acid, stearic acid, behenic acid, lanolin fatty acid, linoleic acid, linolenic acid, lauric acid, myristic acid, oleic acid, isostearic acid, cetanol, stearyl alcohol, Hexyl decanol, otatildo decanol, Laurino Natural and synthetic higher alcohols
- Surfactants include sorbitan monolaurate, sorbitan monopalmitate, sorbitan sesquioleate, sorbitan trioleate, polyoxyethylene sorbitan monolaurate, polyoxetylene sorbitan monostearate, polyethylene glycol monooleate, Polyethyleneglycolanolenochelate, polyoxyethyleneanolenoate ethere, polyglycol gel ether, lauroyl jetanol amide, fatty acid isopropanol amide, maltitol hydroxy fatty acid ether, alkylated polysaccharide, alkyl darco Nonionic surfactants such as sids and sugar esters, lipophilic glycerin monostearate, self-emulsifying glycerin monostearate, polyglycerin monostearate, polydaririne monoanolate, sonolebitan monooleate, polyethylene Nonionic surfactants such as glycolanol monoste
- Preservatives include benzoic acid and its salts, salicylic acid and its salts, sorbic acid and its salts, dehydroacetic acid and its salts, and paraoxybenzoic acid esters such as alkyl esters of parabenzoic acid.
- 1,3-butylene glycol is added to 0.1% to 40%, preferably 1% to 30%, of a cyanobacteria extract to suppress the growth of microorganisms. Odor generation can also be effectively suppressed.
- fragrance benzaldehyde, benzyl benzoate, phenylacetic acid, sandalo nore, eugenol, lilia mononole, rilal, linalool, 2_methyl_3_ (4-methylphenyl) monopropanal, musta ketone, cinnamic aldehyde, belt fixes, methyl Ionon, galley El formate, iso E super, ⁇ Undekarakuton to, Kishirusarishi Exemplified rate, cis-hexhexenoresalicylate, methinoresidhydrodiasmonate, tetrahydrofurfuryl 3_mercaptopropionate, covanol, vanillin, vanillar, gerayu oil, peni royal oil, perch oil, alumois oil, etc. can do. Since these fragrances mask the off-flavors peculiar to plant extracts including the indigo grass extract of the present invention, they can be advantageous
- glycerin As humectants, glycerin, erythritol, xylitol, maltitol glycerin, propylene glycol, 1,3-butylene glycol, sorbitol, maltitol, polyglycerin, polyethylene glycol, dipropylene glycol, 1,2-pentanediol, isoprene glycol, etc.
- one or a combination of two or more selected from treno, loin, trehalose carbohydrate derivatives, cyclic tetrasaccharides, hyaluronic acid and its salts, chondroitin sulfate and its salts, which have strong moisturizing effects, etc. are used. Is desirable.
- thickener examples include sodium alginate, xanthan gum, aluminum oxalate, quince seed extract, gum arabic, hydroxyethyl dagam, carboxymethyl dagam, guar gum, dextran, tragacanth gum, cellulose, starch, punoreran.
- Semi-synthetic polymer materials such as soluble starch, branched starch, and cationized cellulose, synthetic polymer materials such as carboxybule polymer, polyvinyl alcohol, polybutylpyrrolidone, and vinyl alcohol Etc. can be exemplified.
- antioxidants include dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate, L-ascorbic acid, vitamin E, vitamin P, catechins, flavonoids and their derivatives. it can.
- Examples of the chelating agent include edetate disodium, ethylenediamine tetraacetate, pyrophosphate, hexametaphosphate, citrate, tartaric acid, darconic acid and the like.
- Examples of the pH adjuster include sodium hydroxide, potassium hydroxide, triethanolamine, nitric triethanol, citrate, sodium citrate, boric acid, borax, and potassium hydrogen phosphate. Can do.
- UV absorbers / scattering agents include paraaminobenzoic acid UV absorbers, anthranilic acid UV absorbers, salicylic acid UV absorbers, cinnamic acid UV absorbers, benzophenone UV absorbers, and sugar UV absorbers.
- Vitamins other than L-ascorbic acid and its derivatives include vitamin A and its derivatives, vitamin B and its derivatives, vitamin B and its derivatives, vitamin B hydrochloride,
- Vitamin B 1, 2 6 Vitamin B Torinoformate, Vitamin B Dioctanoate, Vitamin B, Vitamin B and
- Vitamin B such as its derivatives, ⁇ -tocopherol, monotocopherol, ⁇ -tocopherol, vitamin ⁇ Acetates and other vitamins ⁇ , vitamin D, vitamin ⁇ , pantothenic acid, panthetin, vitamin F, vitamin Examples include bioflavonoids such as K, rutin 'hesperidin' and naringin and derivatives thereof, vitamin U, ferulic acid, ⁇ -oryzanol, ⁇ -lipoic acid, orotic acid, coenzyme Q10, and their derivatives. It may be a salt of
- amino acids examples include glycine, alanine, valine, leucine, isoleucine, serine, threonine, phenylalanine, tyrosine, wasparagine, glutamine, taurine, tryptophan, cystine, cystine, methionine, proline, hydroxyproline, and aspartic acid.
- Glutamic acid, arginine, histidine, lysine, carnitine, and derivatives thereof, and the like may be used.
- Anti-inflammatory agents include allantoin or its derivatives allantoin, allantoinacetyl dl_methionine, allantoinchlorohydroxyaluminum, allantoindihydroxyaluminum, allantoin polygalacturonic acid, glycyrrhetin or derivatives thereof.
- glycyrrhetinic acid glycyrrhizic acid, glycyrrhetinic acid allantoin, daricylretinoic acid glycerin, glycyrrhetinic acid stearyl, stearic acid glycyrrhetic acid, 3_succinyloxyglycyrrhetinic acid disodium salt, glycyrrhizic acid dipotassium, glycyrrhetinic acid monoammonium, pantothenic alcohol, , Pantotenole echino lee tenor, acechin ole panto teninole echino le ethenore, benzoinole pantoteni Norethyl ether, Calcium pantothenate, Sodium pantothenate, Acetyl pantotenyl ether, Benzoic acid pantotenyl ether ester, Pante
- pantothenic acid vitamin E, d- ⁇ -tocopherol, dl- ⁇ -tocopherol, dl—one tocopherol, linoleic acid— ⁇ -tocopherol, nicotinic acid dl— ⁇ —tocopherol, dl_one tocopherol
- Vitamin E derivatives such as L-ascorbic acid, L-ascorbic acid-2-darcoside and other L-ascorbic acid glycosides, L-ascorbic acid glycosides acylated derivatives, tetrahexyldecanoic acid ascorbic acid, L-ascorbic acid Ascorbic acid-tocopherol phosphoric acid diester L-ascorbic acid sulfate, dipalmitic acid ascorbyl, palmitic acid ascorbyl, L-ascorbic acid stearyl, phosphoric acid-ascorbyl, L-ascorbic acid ester And derivatives of L-scor
- seaweed extracts there are extracts from brown algae, red algae, green algae, cyanobacteria, etc., and specifically, kombu, macombu, wakame, hijiki, proboscis, coral, palmaria, punomata, nori, ryosa.
- Examples include powerful extracts such as Anasa, Ascophyllum, Hibamata, Mozuku, Okina Mozuku, Himantalia. This includes extracts from aquatic plants such as eelgrass.
- the external preparation for skin of the present invention has a blood circulation promoting substance, a substance having an astringent action, a substance having an anti-itching action, a substance having a cell activating action, and an anti-aging activity.
- a blood circulation promoting substance a substance having an astringent action
- a substance having an anti-itching action a substance having a cell activating action
- an anti-aging activity a substance having astringent action
- a substance having an anti-itching action a substance having a cell activating action
- an anti-aging activity a blood circulation promoting substance.
- One or two or more kinds of arbitrary ingredients such as substances having hair growth, substances having hair growth activity, substances having hair growth activity and substances having a transdermal absorption promoting action, and appropriately formulated into a skin external preparation. I can do it.
- Specific examples include, for example, ingredients of plants and animals other than indigo plants such as propolis, Chinese parsley, and other herbs and royal jelly, extracts derived from them
- Minerals such as ingredients, antibiotics, calcium hydrogen phosphate, organically modified montmorillonite, key acid, anhydrous key acid, magnesium silicate, mica, bentonite, titanium-coated mica, oxysalt / bismuth, zirconium oxide, magnesium oxide, Inorganic powders such as zinc oxide, calcium carbonate, magnesium carbonate, iron oxide, ultramarine, bitumen, chromium oxide, chromium hydroxide, calamine, zeolite and force bon black, polyamide, polyester, polyethylene, polypropylene, polystyrene, polyurethane, Bulle resin, urea resin, funnel Resin, Fluoro resin, Key resin, Acrylic acid resin, Melamine resin, Epoxy resin, Polycarbonate resin, Dibutylbenzene / styrene copolymer, Copolymer composed of two or more monomers of the above compounds, Silk, etc.
- Natural colorants such as organic powders such as protein, hard protein, cellulose, safflower, gardenia, sicon, and cochineal, anthraquinone, anthocyanin, chalcone, and carotenoid Element 101, photosensitive element 201, photosensitive element 301, photosensitive element 401 and other photosensitive elements, red 201, red 202, red 204, red 205, red 220, red 226, red 228 No., red 405, orange 203, orange 204, yellow 204, yellow 401 and blue 404 organic pigment powder, red 3, red 104, red 106, red Color 227, red 23 No.
- organic powders such as protein, hard protein, cellulose, safflower, gardenia, sicon, and cochineal, anthraquinone, anthocyanin, chalcone, and carotenoid Element 101, photosensitive element 201, photosensitive element 301, photosensitive element 401 and other photosensitive elements, red 201, red 202
- Organic pigments such as zirconium, barium or aluminum lakes Powder, natural colorants such as sicon and safflower pigments and organic synthetic pigments, transglycosyl rutin, transglycosyl hesperidin, transglycosylglycyrrhizin, transglycosylnardin, estaretin, esculin, transglycosyl esculin, etc. Examples thereof include powders on which the functional components are supported.
- the amount of these substances to be added to the external preparation for skin is not particularly limited as long as it does not interfere with the physical properties of the target external preparation for skin and / or the action and effect of the present invention. Normally, it should be in the range of 0.0001% to 99% of the total mass of the external preparation for skin, preferably 0.001% to 70%, and more preferably 0.01%. A range of up to 30% is preferable.
- the dosage form of the external preparation for skin of the present invention is arbitrary, for example, a solubilizing system such as powder, solid, and lotion, an emulsifying system such as emulsion, cream, and paste, or an ointment, dispersion, etc.
- a solubilizing system such as powder, solid, and lotion
- an emulsifying system such as emulsion, cream, and paste
- an ointment, dispersion etc.
- the external preparation for skin of the present invention refers to an external preparation applied to the outer skin such as the skin and scalp and the mouth as cosmetics, pharmaceuticals, and quasi drugs, such as ointments, creams, emulsions, lotions, Essence, jelly, jewel, pack, mask, bath preparation, powder toothpaste, moisturizing toothpaste, toothpaste, water toothpaste, medicated toothpaste, mouth refreshing agent, mouth refreshing film, mouthwash, mouthwash, etc. Also includes compositions for oral consumption such as gums and candy used for the purpose of maintaining elasticity and color.
- B16 melanoma cells were cultured in the same manner as the extract of cyanobacteria, and the color tone was observed.
- the degree of blackening of B16 melanoma cells was evaluated according to the following criteria, and the results are shown in Table 1.
- cyanobacterium extract does not inhibit tyrosinase activity itself, suppression of melanin production by cyanobacterium extract does not affect tyrosinase. This is thought to be because the synthesis of lysase was suppressed.
- the cyanobacteria extract used in Experiment 1 contained tributanthrine having a final concentration of 0.33 x gZml.
- a test was conducted as follows to examine the effects of the extract of cyanobacteria and other whitening components on melanin production. In other words, for each group of 20 subjects with dark black, stains, and freckles, one group of the following test lotions was applied to the face daily for 3 months in the morning and evening. After a month, the whitening effect was examined.
- test lotion formulation of Experiment 3 above does not have the cyanobacteria extract of (5), and has the whitening action shown in Table 3 as a drug of (6).
- a comparison lotion was prepared using the same formulation, blending amount, and manufacturing method as in Experiment 3, except that any one of the ingredients was added in the amount shown in Table 3. The same as the test lotion in Experiment 3. The whitening effect was evaluated by the method. The results are also shown in Table 3.
- Judgment criteria and judgment of whitening effect test when test lotion and comparative lotion were used were as follows.
- Inhibition rate (%) ⁇ (A-B) / A ⁇ X 100
- the concentration-dependent elastase activity inhibitory effect was observed in the cyanobacteria extract.
- the same experiment was conducted using the Japanese knotweed extract (solid content 1.65%), buckwheat extract (solid content 1 ⁇ 37%) or michanagi extract (solid content 1 ⁇ 81%) used in Experiment 1.
- the concentration of solids that inhibits the enzyme activity of elastase used by 50% was calculated to be 1. l lmg / ml.
- the elastase activity inhibition rate is as low as 12%, 13%, and 25%, respectively, and the concentration that inhibits the activity of elastase used in the experiment by 50% can be calculated. There wasn't.
- This result indicates that the cyanobacteria extract has a strong inhibitory effect on elastase activity compared to the extracts of the same Tedaceae weed, buckwheat or michanagi. This result shows that the external preparation for skin containing a herb extract has an excellent effect of suppressing the occurrence of wrinkles.
- Mcllvaine buffer solution pH 7.4, 0.1 M citrate 9.0.1 M 4_Methylumbelliferyloleate containing 25 ⁇ 1 of the cyanobacteria extract used in Experiment 4 and a test sample diluted with the extract. 15% and 0.2M Na HPO 90.85% contained) 50
- the extract of cyanobacteria suppresses the activity of enzymes that are said to affect human skin aging and wrinkle development. Since it was found to have an effect, the effect on human skin was confirmed by a panel test by volunteer subjects. That is, 35 parts by mass of a 2% aqueous solution of carboxybule polymer, 5 parts by mass of concentrated glycerin, 1.8 parts by mass of a 10% aqueous solution of potassium hydroxide, 3 parts by mass of pentylene glycol, according to the method of Example 1 described later Mix the appropriate amount of the prepared cyanobacteria extract (solid content concentration 1%, 1,3-butylene alcohol) and the appropriate amount of purified water.
- Test jewels were prepared so that the concentrations shown in FIG. As a control, water was used instead of 50 parts by weight of the above-described indigo extract.
- An illumination gel was prepared.
- Sixty volunteer subjects were randomly divided into 6 groups of 10 people, and for each group, 10 test subjects each containing one level of cyanobacteria extract and a control jewel. It was applied to different locations on the inner side of the upper arm three times a day for 56 consecutive days. On the last day of application, twice the amount of minimum erythema (minimum irradiance that induces erythema at the irradiated site for each subject) confirmed by a test in which the dose of ultraviolet rays was changed in advance.
- the control jelly was applied when the compounding amount of the indigo grass extract in the test jewel was 0.05% or more (containing at least 0.0005% in terms of solids).
- the degree of erythema and the evaluation of skin elasticity were both B, and more than half of the subjects showed the effect of applying the test jewel, 0.5% or more (in terms of solids,
- the effect becomes significant when the blending amount is 0.005% or more (contains 0.05% or more in terms of solids), and the occurrence of erythema and the elasticity of the skin are enhanced.
- the evaluations of the properties were all A, and the coating effect became more remarkable.
- the jelly containing 50% of the cyanobacteria extract used in Experiment 8 suppresses the occurrence of erythema due to ultraviolet rays in human skin and significantly enhances skin elasticity. Therefore, in order to further confirm the effect, histological examination of the skin where the cyanobacteria extract was applied was conducted. That is, 35 parts by mass of a 2% aqueous solution of a carboxyvinyl polymer, 5 parts by mass of concentrated glycerin, 1.8 parts by mass of a 10% aqueous solution of potassium hydroxide, 3 parts by mass of pentylene glycol, applied to the method of Example 1 described later.
- a test jewel 50 parts by mass of a cyanobacteria extract (containing 1% solid content, 30% 1,3-butylene glycol) and 5.2 parts by mass of purified water were mixed to prepare a test jewel.
- a control instead of 50 parts by mass of the above-described indigo extract (solid content%), 15 parts by mass of 1,3-butylene glycol was used, and the amount of water added was 40.2 parts by mass.
- a gel was prepared. Volante Test subjects or control jewels were applied to different locations on the inner side of the upper arm of five subjects three times a day for 56 consecutive days.
- each subject was irradiated with ultraviolet rays twice as much as the minimum amount of erythema on the test or control jewel.
- UV irradiation 24 hours later under aseptic xylocaine anesthesia using a commercially available biopsy punch, aseptically irradiated test jewels, places where control jewels were applied, and upper arm without any gel applied Skin tissues were collected one by one from the inner site.
- the collected skin tissue was fixed with formalin by a conventional method, and after paraffin embedding, a tissue section was prepared for histochemical examination.
- Tissue slices were used to measure the thickness of the epidermis and dermis, the number of sunburn cells (dead cells) caused by UV irradiation, and the elastic fiber morphology of the dermis in the elastica 'one-Geeson staining method.
- the thickness of the epidermis layer and the thickness of the dermis layer were measured with an optical microscope, 30 areas selected at random on each tissue section were photographed with a digital camera, the thickness of the corresponding part was measured with calipers, and the average was calculated.
- the average thickness of the area where the test or control jewel was applied was divided by the average thickness of the area where none of the dies were applied to obtain the rate of increase in the thickness of the epidermis or dermis layer (%).
- the average increase rate of five volunteer subjects is calculated and shown in Table 5.
- the number of sunburn cells 30 randomly selected areas were photographed with a digital camera using an optical microscope, the number of sunburn cells recognized in the area was counted, and the average was obtained. Therefore, the average number of sunburn cells in the area where the test or control gel was applied was divided by the average number of sunburn cells in the area where no gel was applied, and the rate of increase in the number of sunburn cells (%) Table 5 shows the average increase rate of five volunteer subjects.
- Control jewel 121 124 147 As is apparent from Table 5, the thickness of the epidermis layer and the thickness of the dermis layer increased at the site where the test or control jewel was applied, compared to the area where none of the dies were applied. In addition, the number of sunburn cells increased. Moreover, the rate of increase in the thickness of the epidermis layer and the dermis layer was higher in the site where the test gel was applied than in the site where the control jewel was applied. Also, the rate of increase in the number of sunburn cells has become low. Furthermore, when observing the elastic fibers with a microscope, a regular arrangement of fibers was observed in the areas where none of the jewels were applied, whereas there was disturbance in the areas where the control gel was applied. It was.
- the results of these experiments indicate that the use of the Aiba extract as an external preparation for skin increases the turnover of cells in the epidermis and dermis layers of the skin and enhances the elasticity of the skin.
- the indigo extract is useful as an anti-aging agent because it can protect the cells from damage caused by ultraviolet rays.
- cyanobacteria extract The following experiment was conducted to investigate the effect of cyanobacteria extract on human oral bacteria. That is, the whole plant of raw indigo plant is cut into small pieces, 3 parts by weight of purified water is added to 2 parts by weight of this, the mixture is stirred for 10 minutes at room temperature, extracted, and then centrifuged. The clean was autoclaved at 120 ° C for 20 minutes. This solution was cooled and then centrifuged again, and the resulting supernatant was filtered to obtain a cyanobacteria extract (solid content 1.41%). Using this extract, the minimum inhibitory concentration (hereinafter sometimes abbreviated as “MIC”) against oral bacteria (periodontal disease-causing bacteria and caries-causing bacteria) was determined. In addition, Table 6 shows the MICs of triptansulin, gallic acid, or caffeic acid, which were confirmed to be contained in the extract of cyanobacteria, for oral bacteria. The MIC was measured by the following method.
- the MICs of cyanobacteria extract, tributanthrine, gallic acid and caffeic acid for oral bacteria were determined according to the standard method of the Japanese Society of Chemotherapy (“Bacteria 'Fungus Test 2nd Edition”, published by the Japan Public Health Association) Pp. 524 to 529 (1982)).
- JMC6301 strain JMC6301 strain was used.
- These microorganisms are brain heart infusion with 5 / ml hemin and 0.5 ⁇ g / ml vitamin ⁇ .
- BHI medium
- periodontal pathogens at 37 ° C for 48 hours, causative bacteria at 37 ° C for 18 to 24 hours, anaerobic Each of them was cultured.
- the broths were prepared by diluting the culture solutions of the periodontal disease causing bacteria and the causative causative bacteria to 10 8 cells / ml and 10 6 cells / ml, respectively. Inoculate 5 ⁇ l of this bacterial solution with agar extract, tributanthrine, gallic acid or caffeic acid at various concentrations, and inoculate them at 37 ° C for 24 hours.
- the cells were cultured in an anaerobic state, and the minimum concentration was set such that the growth of the fungi was completely prevented by these components.
- cyanobacteria extract has strong antibacterial activity against 4 types and 7 strains that are considered to be periodontal disease and 2 types and 7 strains that are considered to be a causative agent.
- the MIC was 1.74 mg / ml to 3.48 mg / ml in terms of solid matter in the extract of cyanobacteria.
- strong antibacterial activity was observed for tributansulin and weak antibacterial activity was also observed for gallic acid and caffeic acid, and their MICs were 6 ⁇ 25 ⁇ g / ml to 25 ⁇ g / ml, 200 ⁇ g / ml, respectively.
- the cyanobacteria extract used in this experiment contains tributanthrine, gallic acid, and caffeic acid in terms of solid content of approximately 0.51 / ig / mg, approximately 0.55 / ig / mg, 1.07 ⁇ g. However, these contents are not sufficient to obtain Ml C against periodontal and causative bacteria of cyanobacteria extract, and the antibacterial activity of cyanobacteria extract against oral bacteria is not sufficient. It was suggested that components other than tributanthrin, gallic acid and caffeic acid were also involved. In addition, the growth inhibitory effect on each oral bacterium used for the measurement of MIC was observed from about 1 / 100th the concentration of MIC of each component, and the effect increased in a concentration-dependent manner.
- a test for confirming the bactericidal action of the cyanobacteria extract against Prophyromonas gingivalis JCM8525 strain used for the measurement of MIC was performed as follows. In other words, for MIC measurement Add the same cyanobacteria extract used in BHI to 6.95mgZml, 3.48mgZml or 1.74mgZml in solid form, and add Proviromonas gingivalis JCM8525 strain was added at 10 8 / ml to maintain the anaerobic state and cultured at 37 ° C for 3 hours or 9 hours. These cultures are appropriately diluted and inoculated on a BHI agar plate and cultured for 24 hours at 37 ° C while maintaining anaerobic conditions.
- the number of colonies formed is counted, and the culture solution before dilution is used. The number of viable bacteria was determined. As a control, the viable cell count after culturing was similarly determined using the viable cell count when cultured in BHI supplemented with deionized water in place of the cyanobacteria extract.
- the JCM8525 strain of Prophyromonas ginginocris cultured in a medium supplemented with 95 mg / ml cyanobacteria extract was completely sterilized after 3 hours of culture. 3.
- 48 mg / ml of cyanobacteria extract was added the number of viable bacteria decreased to 1000 times in 3 hours and to 10,000 times in 9 hours compared to before cultivation. 1.
- 74mg / ml of cyanobacteria extract was added, the number of viable bacteria decreased to about 1/10 in 3 hours and to 1 in 100 minutes in 9 hours.
- Prophyromonas gingivalis decreased in viable cell counts depending on the concentration of the extract and the incubation time with the extract.
- the extract of cyanobacteria of the present invention inhibits melanin production, elastase activity inhibition, lipase activity inhibition, active oxygen removal, radical scavenging, dermal and epidermal cell turnover enhancing action, cell Since it has both effects of protecting against UV damage to skin, the topical skin preparation containing this indigo extract suppresses skin pigmentation after sunburn and buckwheat sunburn, and also causes the formation of wrinkles and koi wrinkles. Since it can suppress skin aging and skin aging, it shows excellent skin whitening, skin beautification and Z or anti-aging effects. It also shows that this indigo extract is excellent in preventing and improving periodontal disease and touch when used as an oral preparation for oral use.
- this product was mixed with 3 parts by mass of 1,3-butylene glycol as a preservative and stirred to prepare an indigo grass extract.
- This product is less stable in terms of generation of starch and off-flavors and browning than those without 1,3-butylene glycol (hereinafter abbreviated as “1,3_BG”). Excellent in properties.
- this product has various physiological activities such as melanin production suppression, elastase inhibitory activity, lipase inhibitory activity, sebum secretion regulating action from sebaceous gland, SOD-like action, DPPH radical scavenging action, and anti-aging action. Therefore, it can be advantageously used as an active ingredient of a skin external preparation for whitening and / or skin beautification and oral cavity.
- the cyanobacteria extract prepared by the method of Example 1 was further filtered through an ultrafiltration membrane to prepare an extract of cyanobacteria.
- This product has little precipitation and turbidity even when stored for a long period of time, and because fine particles have been removed by ultrafiltration, the permeability to a membrane with a pore size of 0. Compared to the standard product without membrane filtration, it is significantly improved (100 times or more), so it can be sterilized with a membrane, and it is a handle of abundant cyanobacteria extract.
- This product is a cyanobacteria extract with reduced browning and off-flavour.
- DPPH radio Since it has various physiological activities such as skin scavenging action and anti-aging action, it can be advantageously used as an active ingredient for skin whitening and / or skin beautification and oral skin preparations.
- the cyanobacteria extract prepared by the method of Example 3 was concentrated 10 times, and 1 part by weight of the branched cyclodextrin (sold by Shimizu Minato Sugar Co., Ltd. (Product name “Iso-Elite P”) 1 part by weight, ⁇ , a Syrup containing ⁇ , a trehalose saccharide derivative (Co., Ltd.) 0.1 part by weight was added, dissolved by stirring, spray-dried in a conventional manner, and extracted from a grass. A product powder was prepared.
- This product is a cyanobacteria extract with excellent storage stability that does not brown even after long-term storage.It suppresses melanin production, inhibits elastase, inhibits lipase, regulates sebum secretion from sebaceous glands, Since it has various physiological activities such as SOD-like action, DPPH radical scavenging action, and anti-aging action, it can be advantageously used as an active ingredient for skin whitening and / or skin beautifying and oral skin preparations.
- a cream was prepared by a conventional method based on the following formulation.
- Pentylene glycol 3.5
- Carbohydrates containing carbohydrate derivatives of a, a -trehalose (sales by Hayashibara Biochemicals, Inc., trade name “Tornale”): 2
- This product is useful as a skin external preparation for whitening, skin beautification and / or anti-aging.
- this product is excellent in skin penetration and spreadability, and has a feature of smoothening the skin slip after application because it contains pullulan.
- a gel was prepared by a conventional method.
- Photosensitive Element 201 0.00
- Carboxybule polymer (sold by Wako Pure Chemicals Co., Ltd., trade name “HIBIS KOKO 104 J): 0. 64 2, 2 ', 2_Nitrotriethanol: 1
- This product is useful as an external preparation for skin whitening, skin beautification and Z or anti-aging.
- this product has excellent skin permeability and spreadability.
- an emulsion was prepared by a conventional method.
- This product is useful as an external preparation for skin whitening, skin beautification and / or anti-aging. In addition, this product has excellent skin permeability and spreadability.
- This product is useful as a skin external preparation for whitening, skin beautification and / or anti-aging. In addition, this product has excellent skin permeability and spreadability.
- a shampoo was prepared by a conventional method based on the following formulation.
- Photosensitive Element 201 0. 002
- Aizusa extract (sales of Hayashibara Biochemicals, Inc., trade name “Ai Luros”, 1, 3-—Aqueous extract of Aizusa containing 30% BG): 5
- This product is a shampoo that has an effect of preventing inflammation and aging of the scalp and has strong antibacterial properties, so it has excellent hair growth effect, suppresses hair loss and keeps the scalp clean.
- a hair tonic was prepared by a conventional method based on the following formulation.
- Photosensitive Element 301 0.00
- Glucose-transferred hesperidin (sales by Hayashibara Biochemicals Co., Ltd., trade name "Alphagnocosyl hesperidin”): 0. 01
- This product is a hair tonic that has the effect of preventing inflammation and aging of the scalp, has strong antibacterial properties, has excellent hair growth effects, suppresses hair loss, and keeps the scalp clean.
- this product promotes the growth of dermal papilla cells when used on a scalp in which the hair root is planted, and has an excellent effect on the rate of growth of the transplanted hair root on the scalp.
- a toothpaste was prepared by a conventional method.
- this product contains an extract of cyanobacteria, it is useful as a cosmetic product that maintains the tension and elasticity of gums, has an anti-inflammatory effect, and maintains or enhances oral health.
- the antibacterial components contained in the extract of cyanobacteria exert bacteriostatic and bactericidal effects against the causative causative bacteria and periodontal causative bacteria on the tooth surface and periodontal disease pockets. It can be advantageously used for prevention, prevention of periodontal disease, and suppression of progression.
- a toothpaste was prepared by a conventional method.
- Carbohydrates containing carbohydrate derivatives of a, a -trehalose (sales of Hayashibara Biochemicals, Inc., trade name “Tornale”): 10
- Titanium oxide 2
- this product contains an extract of cyanobacteria, it is useful as a dentifrice that maintains the tension and elasticity of the gums, has an anti-inflammatory effect, and maintains or enhances oral health.
- the antibacterial components contained in the extract of cyanobacteria exert bacteriostatic and bactericidal effects against the causative causative bacteria and periodontal causative bacteria on the tooth surface and periodontal disease pockets. It can be advantageously used for prevention, prevention of periodontal disease, and suppression of progression.
- a dentifrice was prepared by a conventional method.
- Carbohydrates containing carbohydrate derivatives of a, a -trehalose (sales of Hayashibara Biochemicals, Inc., trade name “Tornale”): 10
- Propolis extract (sales by Hayashibara Biochemical Research Institute): 0.5
- this product contains an extract of cyanobacteria, it is useful as a dentifrice that maintains gum tension and elasticity, has an anti-inflammatory effect, and maintains or promotes oral health.
- the antibacterial components contained in the extract of cyanobacteria exert bacteriostatic and bactericidal effects against the causative causative bacteria and periodontal causative bacteria on the tooth surface and periodontal disease pockets. It can be advantageously used for prevention, prevention of periodontal disease, and suppression of progression.
- a dentifrice was prepared by a conventional method.
- Cyanobacteria extract prepared by the method of Example 3 2 Glucose-transferred hesperidin (Hayashibara Biochemical Laboratories, Inc., trade name " a G Hesperidin”): 1
- the total amount is 100%.
- this product contains an extract of indigo grass, it maintains the tension and elasticity of the gums, improves dry mice due to Shichi- Spotify syndrome, prevents inflammation in the oral cavity and taste disorders, etc. It is a mouthwash that is suitable for treatment and has good strength and feel.
- the antibacterial components contained in the extract of indigo grass have bacteriostatic and bactericidal effects against the causative causative bacteria and periodontal disease causative bacteria on the tooth surface and periodontal disease pockets. It can also be used advantageously for touch prevention, prevention of periodontal disease and suppression of progression.
- An ointment was prepared by a conventional method based on the following formulation.
- This product is useful as an external preparation for skin whitening and / or skin. This product can also be used for the purpose of maintaining and improving the health of the skin, which has excellent skin permeability and spreadability.
- jelly ointment was prepared by a conventional method.
- This product is useful as a skin external preparation for whitening and / or skin. This product also has excellent skin permeability and spreadability, and can be used to maintain and enhance skin health.
- Example 18
- a bath preparation was prepared by a conventional method.
- Hydrous crystal a, hi-trehalose (Hayashibara Biochemical Laboratories Co., Ltd., for cosmetics): 74.4
- the total amount is 100%.
- This product is a bath preparation excellent in whitening and / or skin beautifying effects.
- a mouth-cooling film was prepared by a conventional method.
- Cyanobacteria extract prepared by the method of Example 1 (does not contain 1,3-BG): 3 Emulsified mint oil: 2.6
- this product contains an extract of cyanobacteria, it maintains its gum tension and elasticity, and it is used for the purpose of maintaining and improving oral health by advocating its superior anti-inflammatory effect. can do.
- This product is a refreshing film in the mouth that is also useful for preventing bad breath.
- chewing gum was prepared by a conventional method.
- the total amount is 100%.
- This product contains an extract of cyanobacteria, so it maintains its gums and elasticity, and is used for the purpose of maintaining and improving oral health by advocating its superior anti-inflammatory effect. can do.
- the Cyanobacteria extract of the present invention is excellent in storage stability in which starch and off-flavor are hardly generated and browning is difficult to occur.
- the cyanobacteria extract of the present invention has various physiological activities such as melanin production suppression, elastase inhibitory activity, lipase inhibitory activity, sebum secretion regulating action from sebaceous glands, SOD-like action, DPPH radical scavenging action, etc.
- the topical skin preparation that contains this is effective for lightening and whitening of pigmentation and stains such as 'sobacus' liver spots after sunburn, as well as maintaining the skin tension 'recovers elasticity' due to elastase inhibitory activity.
- the external preparation for skin of the present invention can be further enhanced by using other whitening ingredients in addition to the above-mentioned action, the external preparation for skin of the present invention is used only for the purpose of whitening and skin. In addition, it is also used for the prevention of skin sebum components and skin oxidative damage, skin aging prevention, skin protection, athlete's foot treatment, stomatitis treatment, acne treatment, periodontal disease and touch prevention and treatment. That power S.
- the external preparation for skin of the present invention is safe and free from concerns about side effects, it can be used comfortably for a long time.
- the present invention is an invention that exhibits such remarkable effects, and is a truly significant invention that makes a great contribution to the world.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007517916A JP5085321B2 (ja) | 2005-05-27 | 2006-05-26 | 皮膚外用剤 |
US11/915,608 US20090263339A1 (en) | 2005-05-27 | 2006-05-26 | Agent for external application to the skin |
EP06746884A EP1894558A1 (en) | 2005-05-27 | 2006-05-26 | Agent for external application to the skin |
KR1020077028886A KR101338546B1 (ko) | 2005-05-27 | 2006-05-26 | 피부 외용제 |
CN2006800235706A CN101212952B (zh) | 2005-05-27 | 2006-05-26 | 皮肤外用剂 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005155073 | 2005-05-27 | ||
JP2005-155073 | 2005-05-27 | ||
JP2005-313896 | 2005-10-28 | ||
JP2005313896 | 2005-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006126675A1 true WO2006126675A1 (ja) | 2006-11-30 |
Family
ID=37452097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/310555 WO2006126675A1 (ja) | 2005-05-27 | 2006-05-26 | 皮膚外用剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090263339A1 (ja) |
EP (1) | EP1894558A1 (ja) |
JP (2) | JP5085321B2 (ja) |
KR (1) | KR101338546B1 (ja) |
CN (1) | CN101212952B (ja) |
TW (1) | TW200716198A (ja) |
WO (1) | WO2006126675A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007182420A (ja) * | 2005-12-30 | 2007-07-19 | Ind Technol Res Inst | フリーラジカルを抑制する薬草組成物および該薬草組成物を含む健康食品 |
JP2008297260A (ja) * | 2007-05-31 | 2008-12-11 | Hayashi Shoji Kk | 肌用シート材 |
JP2009242326A (ja) * | 2008-03-31 | 2009-10-22 | Shiseido Co Ltd | 美白液状化粧料 |
JP2011093835A (ja) * | 2009-10-29 | 2011-05-12 | Noevir Co Ltd | 皮膚外用剤 |
JPWO2009116450A1 (ja) * | 2008-03-17 | 2011-07-21 | 株式会社林原生物化学研究所 | エラスターゼ活性阻害剤 |
CN102793640A (zh) * | 2012-08-24 | 2012-11-28 | 胡发刚 | 白癜风遮盖组合物及其制备方法 |
EP2087903A4 (en) * | 2006-11-24 | 2013-07-31 | Hayashibara Biochem Lab | EXTRACT POWDER FROM AN INDIGENOUS PLANT, METHOD FOR THE PRODUCTION THEREOF AND ITS USE |
WO2013150643A1 (ja) * | 2012-04-06 | 2013-10-10 | Horikawa Toyokatsu | ケラチン繊維の修復方法 |
JP2013213018A (ja) * | 2012-03-09 | 2013-10-17 | Sunstar Inc | 藍葉エキス及びヨモギエキスを含有する組成物 |
JP2014043472A (ja) * | 2007-04-09 | 2014-03-13 | Hayashibara Co Ltd | エクオール類を有効成分とする美白剤 |
JPWO2013018827A1 (ja) * | 2011-08-03 | 2015-03-05 | 堺化学工業株式会社 | 分散体 |
US8980336B2 (en) | 2005-12-30 | 2015-03-17 | Industrial Technology Research Institute | Method for inhibiting free radicals |
CN104546619A (zh) * | 2015-01-30 | 2015-04-29 | 曾晓飞 | 一种以珊瑚藻为主的富含欧米伽3脂肪酸的皮肤营养液 |
JP2015129174A (ja) * | 2007-11-14 | 2015-07-16 | オーエムピー インコーポレイテッドOMP,Inc. | 皮膚治療用組成物 |
JP5933525B2 (ja) * | 2011-03-14 | 2016-06-08 | サンスター株式会社 | 藍葉エキス製造方法 |
JP2018052877A (ja) * | 2016-09-29 | 2018-04-05 | 久幸 吉田 | トリプタンスリン含有藍葉溶液製造方法 |
JP2019023215A (ja) * | 2008-08-29 | 2019-02-14 | 日本新薬株式会社 | メイラード反応阻害剤 |
JP2020011930A (ja) * | 2018-07-19 | 2020-01-23 | 株式会社ナガセビューティケァ | 小胞体ストレス改善剤 |
JP2022043964A (ja) * | 2020-09-04 | 2022-03-16 | エムワイ カンパニー,リミテッド | 天然抗菌物質の製造方法及び該製造方法により製造された天然抗菌物質を含む抗菌剤 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI414317B (zh) * | 2008-05-29 | 2013-11-11 | Shiseido Co Ltd | 皮膚外用劑 |
CN101669895B (zh) * | 2009-09-28 | 2013-07-03 | 孙和平 | 一种用于消除皱纹的霜剂及其制备方法 |
DE102009048975A1 (de) * | 2009-10-09 | 2011-04-14 | Beiersdorf Ag | Verwendung von 4-n-Butylresorcin zur Verhinderung oder Verminderung der Diffusion eines oder mehrerer Bestandteile kosmetischer Zubereitung, insbesondere Emulsionen in das die Zubereitung umgebenden Behältermaterial, insbesondere Tuben |
KR101897267B1 (ko) * | 2010-12-29 | 2018-09-11 | 주식회사 엘지생활건강 | 식물 유래 유체를 다량 함유하는 피부외용제 |
JP6050572B2 (ja) * | 2011-08-10 | 2016-12-21 | ロート製薬株式会社 | 弾性線維形成促進剤 |
JP6050573B2 (ja) * | 2011-08-10 | 2016-12-21 | ロート製薬株式会社 | Ltbp−4産生促進剤 |
JP6099397B2 (ja) * | 2012-06-28 | 2017-03-22 | 株式会社 資生堂 | ローズマリーエキス及び酢酸レチノールを含むヒアルロン酸分解抑制剤 |
JP2014189512A (ja) * | 2013-03-26 | 2014-10-06 | Okinawa Tokusan Hanbai Co Ltd | フローラルウォーター含有化粧料及びその生産方法 |
CN105263486A (zh) | 2013-04-04 | 2016-01-20 | 现代药品株式会社 | 改善了皮肤渗透的外用剂组合物 |
KR101669626B1 (ko) | 2013-11-29 | 2016-10-26 | (주)에스.앤.디 | 색소 침착의 예방·치료용 조성물 |
CN104434707A (zh) * | 2014-12-30 | 2015-03-25 | 罗友群 | 美白祛斑精华 |
KR101726814B1 (ko) | 2015-03-19 | 2017-04-26 | 경북대학교 산학협력단 | 새우말 추출물을 유효성분으로 함유하는 조성물 |
JP2016199516A (ja) * | 2015-04-13 | 2016-12-01 | キユーピー株式会社 | ゲル状化粧料 |
JP6576194B2 (ja) * | 2015-09-30 | 2019-09-18 | アース製薬株式会社 | 発泡性圧縮成形型入浴剤 |
KR101989034B1 (ko) * | 2016-12-07 | 2019-06-13 | 농업회사법인 주식회사 제주인디 | 쪽꽃 추출물을 함유하는 화장료 조성물 |
KR102111085B1 (ko) * | 2017-09-14 | 2020-05-20 | 농업회사법인(주)제주인디 | 누룩을 이용한 쪽 발효방법 및 이에 얻은 쪽 발효추출물을 이용한 화장료 조성물 |
WO2019094631A1 (en) | 2017-11-08 | 2019-05-16 | Washington University | Compounds and methods for treating bacterial infections |
CN112218616A (zh) | 2018-03-23 | 2021-01-12 | 玫琳凯有限公司 | 局部用组合物和方法 |
IL277940B2 (en) * | 2018-04-12 | 2024-11-01 | Michael EINZIGER | Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof |
CN110037974A (zh) * | 2019-01-21 | 2019-07-23 | 四川省中医药科学院 | 一种具有护肤功效的外用组合物及其制备方法 |
JP7666898B2 (ja) | 2020-04-14 | 2025-04-22 | 花王株式会社 | 口腔内塗布用組成物 |
CN111840160B (zh) * | 2020-08-11 | 2022-02-25 | 广州鹰远生物科技有限公司 | 一种含苏木提取物的组合物及其在皮肤外用剂中的应用 |
CN112641681A (zh) * | 2021-01-08 | 2021-04-13 | 上海彤颜实业有限公司 | 一种植物抑菌组合物及其应用 |
KR102686623B1 (ko) * | 2021-03-31 | 2024-07-18 | 주식회사 송이산업 | 기능성 마스크용 시트 제조방법 및 제조된 기능성 마스크용 시트 |
WO2022265935A1 (en) * | 2021-06-14 | 2022-12-22 | Genomatica, Inc. | 1,3-butylene glycol compositions and methods of use thereof |
CN114099366B (zh) * | 2021-11-17 | 2023-06-20 | 珠海安肽生物医药技术开发有限公司 | 一种促进细胞能量代谢的无菌抗衰祛皱组合液及其制备方法和应用 |
CN114983849B (zh) * | 2022-01-10 | 2023-08-01 | 宁波楚月新材料科技有限公司 | 一种单组分低过氧化氢浓度可见光催化牙齿美白凝胶及制备和应用 |
CN114712517B (zh) * | 2022-05-06 | 2023-07-25 | 蓝科医美科学技术(吉林)有限公司 | 一种泊洛沙姆外用凝胶剂及其制备方法 |
CN118806612B (zh) * | 2024-09-11 | 2024-12-20 | 杭州岛屿星晴生物技术有限公司 | 一种负载愈创薁的油包油微囊及其制备方法和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000344622A (ja) * | 1999-03-31 | 2000-12-12 | Sunstar Inc | スチルベン系化合物及びそれを含有する植物抽出物の安定化およびスチルベン系化合物及びそれを含有する植物抽出物を安定配合した食品、医薬品、化粧品、口腔製剤 |
JP2001069948A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 老化防止用食品 |
WO2003066433A1 (en) * | 2002-02-06 | 2003-08-14 | Honeywell International, Inc. | Apparatus for emergency aircraft guidance |
JP2004115381A (ja) * | 2002-09-24 | 2004-04-15 | Shiseido Co Ltd | 皮膚外用剤 |
JP2004189732A (ja) * | 2002-11-28 | 2004-07-08 | Tohoku Techno Arch Co Ltd | 藍草から得られた抗菌活性物質及びこれを含有する各種組成物 |
JP2005179216A (ja) * | 2003-12-17 | 2005-07-07 | Nomura:Kk | インディカン含有皮膚外用剤 |
JP2005281253A (ja) * | 2004-03-30 | 2005-10-13 | Nof Corp | 皮膚化粧料 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270780B1 (en) * | 1997-07-25 | 2001-08-07 | Chesebrough-Pond's Usa Co., Division Of Conopco | Cosmetic compositions containing resveratrol |
US6524625B2 (en) * | 1998-06-30 | 2003-02-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyuto | Physiologically active extract obtained from indigo plant polygonum tinctorium |
JP4817087B2 (ja) * | 1998-06-30 | 2011-11-16 | 株式会社林原生物化学研究所 | 生理活性抽出物 |
JP3839618B2 (ja) * | 1999-05-13 | 2006-11-01 | 株式会社ノエビア | エラスターゼ阻害剤、及びこれを含有して成る老化防止用皮膚外用剤 |
JP4901025B2 (ja) * | 2001-06-22 | 2012-03-21 | 株式会社ナリス化粧品 | エラスターゼ阻害剤 |
KR100777554B1 (ko) * | 2001-11-08 | 2007-11-16 | 주식회사 엘지생활건강 | 시토스테롤을 함유하는 피부미백용 조성물 |
JP4129574B2 (ja) * | 2002-08-06 | 2008-08-06 | 大塚製薬株式会社 | 老化防止剤 |
JP2004115465A (ja) * | 2002-09-27 | 2004-04-15 | Akaza:Kk | 養毛剤及びそれを用いた養毛方法 |
US7854922B2 (en) * | 2003-02-13 | 2010-12-21 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Skin preparation for external use characterized by containing sugar derivative of α, α-trehalose |
JP2004359602A (ja) * | 2003-06-04 | 2004-12-24 | Shiseido Co Ltd | 皮膚外用剤 |
KR20050077310A (ko) * | 2004-01-27 | 2005-08-02 | 주식회사 엘지생활건강 | 인디고 추출물을 이용한 모발, 눈썹 및 속눈썹 성장촉진제 |
WO2005087182A1 (ja) * | 2004-03-17 | 2005-09-22 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 機能性粉体 |
-
2006
- 2006-05-26 JP JP2007517916A patent/JP5085321B2/ja active Active
- 2006-05-26 CN CN2006800235706A patent/CN101212952B/zh not_active Expired - Fee Related
- 2006-05-26 WO PCT/JP2006/310555 patent/WO2006126675A1/ja active Application Filing
- 2006-05-26 TW TW095118915A patent/TW200716198A/zh unknown
- 2006-05-26 US US11/915,608 patent/US20090263339A1/en not_active Abandoned
- 2006-05-26 EP EP06746884A patent/EP1894558A1/en not_active Withdrawn
- 2006-05-26 KR KR1020077028886A patent/KR101338546B1/ko not_active Expired - Fee Related
-
2012
- 2012-07-06 JP JP2012152585A patent/JP2012184270A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000344622A (ja) * | 1999-03-31 | 2000-12-12 | Sunstar Inc | スチルベン系化合物及びそれを含有する植物抽出物の安定化およびスチルベン系化合物及びそれを含有する植物抽出物を安定配合した食品、医薬品、化粧品、口腔製剤 |
JP2001069948A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 老化防止用食品 |
WO2003066433A1 (en) * | 2002-02-06 | 2003-08-14 | Honeywell International, Inc. | Apparatus for emergency aircraft guidance |
JP2004115381A (ja) * | 2002-09-24 | 2004-04-15 | Shiseido Co Ltd | 皮膚外用剤 |
JP2004189732A (ja) * | 2002-11-28 | 2004-07-08 | Tohoku Techno Arch Co Ltd | 藍草から得られた抗菌活性物質及びこれを含有する各種組成物 |
JP2005179216A (ja) * | 2003-12-17 | 2005-07-07 | Nomura:Kk | インディカン含有皮膚外用剤 |
JP2005281253A (ja) * | 2004-03-30 | 2005-10-13 | Nof Corp | 皮膚化粧料 |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980336B2 (en) | 2005-12-30 | 2015-03-17 | Industrial Technology Research Institute | Method for inhibiting free radicals |
JP2007182420A (ja) * | 2005-12-30 | 2007-07-19 | Ind Technol Res Inst | フリーラジカルを抑制する薬草組成物および該薬草組成物を含む健康食品 |
EP2087903A4 (en) * | 2006-11-24 | 2013-07-31 | Hayashibara Biochem Lab | EXTRACT POWDER FROM AN INDIGENOUS PLANT, METHOD FOR THE PRODUCTION THEREOF AND ITS USE |
JP2014043472A (ja) * | 2007-04-09 | 2014-03-13 | Hayashibara Co Ltd | エクオール類を有効成分とする美白剤 |
JP2008297260A (ja) * | 2007-05-31 | 2008-12-11 | Hayashi Shoji Kk | 肌用シート材 |
JP2015129174A (ja) * | 2007-11-14 | 2015-07-16 | オーエムピー インコーポレイテッドOMP,Inc. | 皮膚治療用組成物 |
US9883998B2 (en) | 2007-11-14 | 2018-02-06 | Omp, Inc. | Methods for lightening skin using arbutin compositions |
JP5551582B2 (ja) * | 2008-03-17 | 2014-07-16 | 株式会社林原 | 皮膚外用剤 |
JPWO2009116450A1 (ja) * | 2008-03-17 | 2011-07-21 | 株式会社林原生物化学研究所 | エラスターゼ活性阻害剤 |
JP2009242326A (ja) * | 2008-03-31 | 2009-10-22 | Shiseido Co Ltd | 美白液状化粧料 |
JP2019023215A (ja) * | 2008-08-29 | 2019-02-14 | 日本新薬株式会社 | メイラード反応阻害剤 |
JP2011093835A (ja) * | 2009-10-29 | 2011-05-12 | Noevir Co Ltd | 皮膚外用剤 |
JP5933525B2 (ja) * | 2011-03-14 | 2016-06-08 | サンスター株式会社 | 藍葉エキス製造方法 |
JPWO2013018827A1 (ja) * | 2011-08-03 | 2015-03-05 | 堺化学工業株式会社 | 分散体 |
JP2013213018A (ja) * | 2012-03-09 | 2013-10-17 | Sunstar Inc | 藍葉エキス及びヨモギエキスを含有する組成物 |
WO2013150643A1 (ja) * | 2012-04-06 | 2013-10-10 | Horikawa Toyokatsu | ケラチン繊維の修復方法 |
JP5380759B1 (ja) * | 2012-04-06 | 2014-01-08 | 豊勝 堀川 | ケラチン繊維の修復方法 |
CN102793640B (zh) * | 2012-08-24 | 2013-07-10 | 胡发刚 | 白癜风遮盖组合物及其制备方法 |
CN102793640A (zh) * | 2012-08-24 | 2012-11-28 | 胡发刚 | 白癜风遮盖组合物及其制备方法 |
CN104546619B (zh) * | 2015-01-30 | 2017-12-08 | 曾晓飞 | 一种以珊瑚藻为主的富含欧米伽3脂肪酸的皮肤营养液 |
CN104546619A (zh) * | 2015-01-30 | 2015-04-29 | 曾晓飞 | 一种以珊瑚藻为主的富含欧米伽3脂肪酸的皮肤营养液 |
JP2018052877A (ja) * | 2016-09-29 | 2018-04-05 | 久幸 吉田 | トリプタンスリン含有藍葉溶液製造方法 |
WO2018062543A1 (ja) * | 2016-09-29 | 2018-04-05 | 久幸 吉田 | トリプタンスリン含有藍葉溶液製造方法 |
JP2020011930A (ja) * | 2018-07-19 | 2020-01-23 | 株式会社ナガセビューティケァ | 小胞体ストレス改善剤 |
JP7210176B2 (ja) | 2018-07-19 | 2023-01-23 | 株式会社ナガセビューティケァ | 小胞体ストレス改善剤 |
JP2022043964A (ja) * | 2020-09-04 | 2022-03-16 | エムワイ カンパニー,リミテッド | 天然抗菌物質の製造方法及び該製造方法により製造された天然抗菌物質を含む抗菌剤 |
JP7219491B2 (ja) | 2020-09-04 | 2023-02-08 | エムワイ カンパニー,リミテッド | 天然抗菌物質の製造方法及び該製造方法により製造された天然抗菌物質を含む抗菌剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2012184270A (ja) | 2012-09-27 |
US20090263339A1 (en) | 2009-10-22 |
TW200716198A (en) | 2007-05-01 |
JP5085321B2 (ja) | 2012-11-28 |
CN101212952B (zh) | 2012-02-08 |
KR101338546B1 (ko) | 2013-12-06 |
JPWO2006126675A1 (ja) | 2008-12-25 |
EP1894558A1 (en) | 2008-03-05 |
CN101212952A (zh) | 2008-07-02 |
KR20080012958A (ko) | 2008-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5085321B2 (ja) | 皮膚外用剤 | |
JP5654731B2 (ja) | 藍草抽出物粉末とその製造方法及びその藍草抽出物粉末の用途 | |
JP5683134B2 (ja) | 皮膚外用剤 | |
TW201438757A (zh) | 抗老化用之皮膚外用組成物及其製造方法 | |
WO2009116450A1 (ja) | エラスターゼ活性阻害剤 | |
JP5072369B2 (ja) | 幹細胞増殖因子発現上昇抑制剤及び塩基性線維芽細胞増殖因子発現上昇抑制剤 | |
JP2011246353A5 (ja) | ||
JP6729913B2 (ja) | 抗炎症剤 | |
JP2014214139A (ja) | Nadh産生促進剤 | |
JP5669436B2 (ja) | 組成物 | |
JP2011241164A5 (ja) | ||
JP2010018545A (ja) | 活性酸素消去剤、皮膚外用剤、口腔用組成物及び食品 | |
JP2004359603A (ja) | 細胞死抑制剤 | |
JP4524221B2 (ja) | 皮膚外用剤 | |
KR20200066443A (ko) | 안토시아닌-폴리사카라이드 복합체를 유효성분으로 포함하는, 노화 또는 노화 관련 질환 예방 또는 치료용 약학적 조성물 | |
JP2013224318A (ja) | 活性酸素消去剤、皮膚外用剤、口腔用組成物及び食品 | |
JP5313524B2 (ja) | 抗炎症剤及び抗炎症用皮膚外用剤 | |
JPWO2012098664A1 (ja) | 3−ヒドロキシ−2−ピロンを含有する美白剤 | |
JP2005281174A (ja) | 活性酸素消去剤 | |
JP2023102221A (ja) | 皮膚外用剤 | |
KR20210006687A (ko) | 신규 파에니스포로사르키나 퀴스퀼리아룸 17mud 1-1541 균주 및 이의 용도 | |
KR20220088317A (ko) | 발효 프로폴리스를 포함하는 항노화 조성물 | |
WO2003047565A1 (fr) | Inhibiteurs de melanogenese et agents blanchissants renfermant des derives d'egonol, et compositions contenant ces derives | |
JP6117607B2 (ja) | メイラード反応生成物濃度低下剤 | |
JP2023031253A (ja) | 皮膚外用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680023570.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007517916 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11915608 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077028886 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006746884 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |